These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31394498)

  • 1. Chronotherapeutic effect of orexin antagonists on glucose metabolism in diabetic mice.
    Kon K; Tsuneki H; Ito H; Takemura Y; Sato K; Yamazaki M; Ishii Y; Sasahara M; Rudich A; Maeda T; Wada T; Sasaoka T
    J Endocrinol; 2019 Aug; ():. PubMed ID: 31394498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resting phase-administration of lemborexant ameliorates sleep and glucose tolerance in type 2 diabetic mice.
    Tsuneki H; Sugiyama M; Sato K; Ito H; Nagai S; Kon K; Wada T; Kobayashi N; Okada T; Toyooka N; Kawasaki M; Ito T; Otsubo R; Okuzaki D; Yasui T; Sasaoka T
    Eur J Pharmacol; 2023 Dec; 961():176190. PubMed ID: 37952563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
    Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
    Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice.
    Etori K; Saito YC; Tsujino N; Sakurai T
    Front Neurosci; 2014; 8():8. PubMed ID: 24550770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
    Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
    BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.
    Coborn JE; DePorter DP; Mavanji V; Sinton CM; Kotz CM; Billington CJ; Teske JA
    Int J Obes (Lond); 2017 Aug; 41(8):1256-1262. PubMed ID: 28392556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
    Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
    Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement.
    Illenberger JM; Flores-Ramirez FJ; Pascasio G; Matzeu A; Martin-Fardon R
    Neuropharmacology; 2023 Nov; 239():109685. PubMed ID: 37579870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.
    Mavanji V; Perez-Leighton CE; Kotz CM; Billington CJ; Parthasarathy S; Sinton CM; Teske JA
    Sleep; 2015 Sep; 38(9):1361-70. PubMed ID: 25845696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
    Khoo SY; Brown RM
    CNS Drugs; 2014 Aug; 28(8):713-30. PubMed ID: 24942635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of orexin receptor antagonism on human sleep architecture: A systematic review.
    Clark JW; Brian ML; Drummond SPA; Hoyer D; Jacobson LH
    Sleep Med Rev; 2020 Oct; 53():101332. PubMed ID: 32505969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
    Tsuneki H; Wada T; Sasaoka T
    Pharmacol Ther; 2018 Jun; 186():25-44. PubMed ID: 29289556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats.
    Fox SV; Gotter AL; Tye SJ; Garson SL; Savitz AT; Uslaner JM; Brunner JI; Tannenbaum PL; McDonald TP; Hodgson R; Yao L; Bowlby MR; Kuduk SD; Coleman PJ; Hargreaves R; Winrow CJ; Renger JJ
    Neuropsychopharmacology; 2013 Nov; 38(12):2401-8. PubMed ID: 23722242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
    Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
    Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain.
    McDonald T; Liang HA; Sanoja R; Gotter AL; Kuduk SD; Coleman PJ; Smith KM; Winrow CJ; Renger JJ
    J Neurogenet; 2016 Mar; 30(1):32-41. PubMed ID: 27276194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.
    Gotter AL; Winrow CJ; Brunner J; Garson SL; Fox SV; Binns J; Harrell CM; Cui D; Yee KL; Stiteler M; Stevens J; Savitz A; Tannenbaum PL; Tye SJ; McDonald T; Yao L; Kuduk SD; Uslaner J; Coleman PJ; Renger JJ
    BMC Neurosci; 2013 Aug; 14():90. PubMed ID: 23981345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.